top of page

Sanifit starts first clinical trial of SNF472 in patients with calciphylaxis

Laboratoris Sanifit has started the first clinical trial of its lead candidate, SNF472, for the treatment of the orphan disease calciphylaxis (calcific uraemic arteriolopathy, CUA).

The recently initiated Phase II study is the first clinical investigation of SNF472 in patients with newly diagnosed calciphylaxis.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page